Thiel J, et al. - This study entails a comparative assessment of the long-term efficacy and safety profile of rituximab (RTX) versus conventional immunosuppressive therapy with cyclophosphamide (CYC), as induction therapies, in eosinophilic granulomatosis with polyangiitis (EGPA). In EGPA patients, RTX effectively afforded remission induction and continued to be effective during long-term follow-up, even when previously refractory to standard immunosuppressive therapy including CYC. Notably, surveillance for hypogammaglobulinemia was recommended in RTX-treated patients.